Second study shows similar rates of SARS-CoV-2 RNA shedding and viral rebound for those receiving nirmatrelvir/ritonavir or placebo
Second study shows similar rates of SARS-CoV-2 RNA shedding and viral rebound for those receiving nirmatrelvir/ritonavir or placebo